NEW YORK, Dec. 19, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 23 companies including many key and niche players such as -
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck & Co, Inc.
Mitsubishi Tanabe Pharma Corporation
Read the full report: http://www.reportlinker.com/p03846707-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-2 Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW.............. II-1 Outlook for DPP-IV Therapies Remains Robust II-1 Major Events in the DPP-IV Inhibitor Space II-2 Table 1: Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date II-3 TECOS Results Prove Superiority of Januvia among Gliptins II-3 Huge Potential Exists for Januvia and Other DPP-4 Inhibitors II-3 Table 2: Global DPP-4 Inhibitor Market by Top Five Drug Class (2015): Percentage Market Share Breakdown of Revenues (includes corresponding Graph/Chart) II-4 The Diabetes Epidemic..............II-4 Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market.............. II-5 Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 Years to Treat Diabetes and Manage Associated Complications (includes corresponding Graph/Chart).............. II-5 Overview of Drug Classes in Anti-Diabetic Drugs Category II-5 Complicated T2DM Management Protocol and the Role of DPP-IV Inhibitors.............. II-6 DPP-4 Inhibitors - Complementing Existing Approaches II-7 Rationale for Use of DPP-4 Inhibitors II-7 Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction II-8 Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market II-8 DPP-4 Inhibitors versus GLP-1 Receptor Agonists II-8 Distinction between GLP-1 Receptor Agonists and DPP-4 Inhibitors II-9 DPP-4 Inhibitors versus Sulfonylureas II-9
2. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS II-10 The DPP-4 Inhibitor Domain..............II-10 Select Approved DPP-4 Inhibitors Available in Developed Markets II-11 Januvia - The Leading DPP-IV Inhibitor Drug Worldwide II-11 Galvus Sales Garner Significant Growth II-12 A Comparison of Januvia and Galvus II-12 Pharmacological Comparison of Sitagliptin and Vildagliptin II-12 Januvia® Franchise (Merck & Co.) II-12 Table 4: Global Sales of Januvia (Sitagliptin) Franchise by Region (2016E, 2018E, 2020E & 2022E): Value Sales in US$ Million for US and RoW(includes corresponding Graph/Chart) II-13 Implantable Drug Pump: Potential Threat to Januvia? II-13 Galvus (Novartis).............. II-14 Onglyza (AstraZeneca)..............II-14 Table 5: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2016, 2018, 2020 & 2022): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart) II-15 Tradjenta (Boehringer Ingelheim) II-15 TENELIA (Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Co., Ltd.).............. II-16 Nesina (Takeda Pharmaceutical) II-16 ZAFATEK (Takeda Pharmaceutical)..............II-16 MARIZEV (Merck).............. II-17 Pipeline Analysis.............. II-17 DPP-IV Inhibitor Pipeline..............II-17 Dutogliptin Development Shelved..............II-18
3. DIABETES INCIDENCE AND PREVALENCE II-19 Table 6: Global Diabetes Mellitus Incidence among Ages 20-79 (2015 & 2040P): Prevalence (in Million) and Percentage Share by Geographic Region (includes corresponding Graph/Chart) II-19
Table 7: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2015 (includes corresponding Graph/Chart) II-20 Diabetes Mellitus Cases Worldwide - A Demographic Analysis by Geographic Region..............II-20 North America.............. II-20 The United States.............. II-20 Canada.............. II-20 Mexico.............. II-20 Table 8: Prevalence of Diabetes Mellitus in North America (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for the US, Canada and Mexico (includes corresponding Graph/Chart)..............II-21 Europe.............. II-21 Table 9: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region II-22 Asia-Pacific.............. II-23 Table 10: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka II-23
Table 11: Prevalence of Diabetes Mellitus in Western Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region II-24 South & Central America..............II-24 Table 12: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region.............. II-25 Rest of World.............. II-26 Table 13: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region II-26
Table 14: Prevalence of Diabetes Mellitus in The Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region.............. II-27
4. DPP-IV INHIBITORS - AN OVERVIEW OF THE DRUG CLASS II-28 Physiology of Glucose Homeostasis II-28 Glucose Homeostasis in the Fasting Stage II-28 Glucose Homeostasis in the Fed Stage II-28 What is DPP-4?.............. II-28 Introduction to DPP-4 Inhibitors II-28 Mechanism of Action of DPP-4 Inhibitors II-29 Schematic Representation of DPP-IV Inhibitor' Mechanism of Action.............. II-29 DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications.............. II-29 Advantages of DPP-4 Inhibitors II-29 Type-2 Diabetes - The Most Prevalent Form of Diabetes II-30 Bio-chemistry of T2DM..............II-30
5. PRODUCT APPROVALS/INTRODUCTIONS II-31 Mankind Pharma Launches Affordable Teneligliptin Drug II-31 Zydus Cadila to Launch Tenglyn II-31 Dong-A ST's Evogliptin Drug SUGANON Receives Approval II-31 PMDA Approves Merck's MARIZEV® (omarigliptin) for Type 2 Diabetes II-31 Glenmark Launches Teneligliptin under Ziten and Zita Plus Brands II-31 Takeda Launches ZAFATEK..............II-31 FDA Approves Glyxambi (linagliptin) by Boehringer and Lilly II-31 EC Approves Takeda's Alogliptin Fixed-Dose Combination Therapies II-32 Mitsubishi Receives Approval for Partial Change in Indication for TENELIA.............. II-32 CFDA Approves Takeda's NESINA..............II-32 USFDA Approves Takeda's NESINA, KAZANO and OSENI II-32
6. RECENT INDUSTRY ACTIVITY..............II-33 FDA Issues Heart Failure Risk Warning to Saxagliptin and Alogliptin Medicines..............II-33 First Real-world Evidence Hints at Greater Efficacy of SGLT2 Inhibitors.............. II-33 FDA Issues CRL to AstraZeneca Regarding Investigational Drug II-33 Lupin and Boehringer Announce Co-Marketing Agreement II-33 FDA Issues Safety Warning about DPP-4 Inhibitors II-33 Merck's TECOS Trial Meets Primary Endpoint II-33 AstraZeneca Enters into Distribution Agreement with Dr.Reddy's II-34 AstraZeneca Files Lawsuit against Mylan for Patent Violation on Onglyza.............. II-34 BMS Completes Sale of Diabetes Business to AstraZeneca II-34 Merck to Discontinue JUVISYNC Distribution to Pharmacies II-34 Takeda and Sanofi Sign Co-Agreement to Market Alogliptin in China II-34 Otsuka Pharmaceutical Receives Marketing Approval for Onglyza II-34
7. FOCUS ON SELECT GLOBAL PLAYERS..............II-35 AstraZeneca Plc. (UK)..............II-35 Boehringer Ingelheim GmbH (Germany) II-35 Eli Lilly and Company (US)..............II-36 Merck & Co, Inc. (US)..............II-36 Mitsubishi Tanabe Pharma Corporation (Japan) II-37 Novartis AG (Switzerland)..............II-37 Takeda Pharmaceutical Company Limited (Japan) II-38
8. GLOBAL MARKET PERSPECTIVE..............II-39 Table 15: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-39
Table 16: World Historic Review for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-40
Table 17: World 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. II-41
Table 18: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-42
Table 19: World Historic Review for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-43
Table 20: World 14-Year Perspective for DPP-IV Inhibitors by Drug Class - Percentage Breakdown of Dollar Sales for Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-44
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 DPP-4 Inhibitors Set to Gain High Share in US Oral Anti- Diabetic Market..............III-1 List of FDA-Approved DPP-4 Inhibitors in the US: 2016 III-2 Diabetes Pandemic in the US..............III-2 Table 21: Prevalence of Diabetes Mellitus in the US (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group (includes corresponding Graph/Chart) III-3 Categories in Diabetes Treatment Market III-3 Table 22: The US Anti-Diabetic Market by Drug Class (2015): Percentage Share Breakdown of Revenues for Insulin, DPP-4 & SGLT-2 Inhibitors, GLP-1 Analogues, Glitazones, PPARs, and Biguanides (includes corresponding Graph/Chart) III-4 Increased Diabetes Spending Favors the DPP-4 Inhibitor Market III-4 Januvia Leads the Way, Will Continue to Maintain Dominance Through 2022.............. III-4 Table 23: The US DPP-4 Inhibitors Market by Leading Brands (2016): Percentage Market Share Breakdown of Revenues for Januvia, Janumet, Tradjenta, Onglyza, Janumet XR, Kombiglyze, and Others (includes corresponding Graph/Chart) III-5 Minimal Differentiation Affects Sales of Onglyza III-5 Table 24: The US Anti-Diabetes Drugs in terms of Total Prescriptions (2015): Percentage Share of Metformin, Sulfonylureas, and DPP-4 Inhibitors (Januvia, Onglyza, Tradjenta & Other) to the Total Non-Insulin Prescriptions (includes corresponding Graph/Chart) III-5 FDA's Issue of Safety Warning on DPP-4 Inhibitors - Potential Market Threat..............III-6 Increasing Scrutiny of NDAs Delays Time-to- Market for New Drugs.............. III-6 Product Approvals.............. III-7 Strategic Corporate Developments III-7 Select Key Players..............III-9 B.Market Analytics..............III-11 Table 25: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-11
Table 26: The US Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-12
Table 27: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-13
Table 28: The US 7-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart) III-14
Table 29: The US Recent Past, Current and Future Analysis for DPP-IV Inhibitor Prescriptions by Drug Compound: Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Number of Prescriptions in Thousands for Years 2015 through 2022 (includes corresponding Graph/Chart) III-15
Table 30: The US 7-Year Perspective for DPP-IV Inhibitors Prescriptions by Drug Compound - Percentage Breakdown of Prescriptions for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)..............III-16
2. CANADA.............. III-17 A.Market Analysis.............. III-17 Table 31: Prevalence of Diabetes Mellitus in Canada (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for Canada (includes corresponding Graph/Chart) III-17 B.Market Analytics..............III-18 Table 32: Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-18
Table 33: Canadian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-19
3. JAPAN.............. III-20 A.Market Analysis.............. III-20 Japan - An Important Market for DPP-IV Inhibitors III-20 Table 34: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart) III-20 Competition in the Japanese DPP-IV Inhibitor Market Heats Up III-20 List of DPP-4 Inhibitors in the Japanese Market (2016) III-21 Product Approvals/Launches..............III-21 Select Key Players..............III-22 B.Market Analytics..............III-23 Table 35: Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-23
Table 36: Japanese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-24
4. EUROPE.............. III-25 A.Market Analysis.............. III-25 Current & Future Analysis..............III-25 DPP-IV Inhibitors Available in the European Market III-25 Prevalence of Diabetes in Europe: Aging Population Dominate III-25 Table 37: Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region III-26 Treatment Strategies of Type-2 Diabetes in Europe III-27 Product Approval..............III-27 B.Market Analytics..............III-28 Table 38: European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-28
Table 39: European Historic Review for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-29
Table 40: European 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Russia, and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-30
4a. FRANCE.............. III-31 Market Analysis.............. III-31 Table 41: French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-31
Table 42: French Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-32
4b. GERMANY.............. III-33 A.Market Analysis.............. III-33 Boehringer Ingelheim GmbH - A Key Player III-33 B.Market Analytics..............III-34 Table 43: German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-34
Table 44: German Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-35
4c. ITALY.............. III-36 Market Analysis.............. III-36 Table 45: Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-36
Table 46: Italian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-37
4d. THE UNITED KINGDOM..............III-38 A.Market Analysis.............. III-38 Strategic Corporate Development III-38 Astrazeneca plc. - a key player III-38 B.Market Analytics..............III-39 Table 47: The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-39
Table 48: The UK Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-40
4e. RUSSIA.............. III-41 Market Analysis.............. III-41 Table 49: Russian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-41
Table 50: Russian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-42
4f. REST OF EUROPE.............. III-43 A.Market Analysis.............. III-43 Novartis Ag - A Key Switzerland-Based Player III-43 B.Market Analytics..............III-44 Table 51: Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-44
Table 52: Rest of European Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-45
5. ASIA-PACIFIC.............. III-46 A.Market Analysis.............. III-46 Asia-Pacific: The Fastest Growing Market for DPP-IV Inhibitors III-46 Aging Populace - Potential Opportunities III-46 Table 53: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)..............III-46 China & India Offer High Potential III-46 Rising Diabetes Incidence in Asia-Pacific Offers Significant Growth Opportunities..............III-47 Table 54: Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka III-47
Table 55: Prevalence of Diabetes Mellitus in Western Asia-Pacific Regions (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region.............. III-48 Asia Suffers from Lack of Focus on Diabetes Care III-48 Healthcare Societies and Associations Spread Awareness of Diabetes.............. III-49 B.Market Analytics..............III-50 Table 56: Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-50
Table 57: Asia-Pacific Historic Review for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-51
Table 58: Asia-Pacific 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, South Korea, and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-52
5a. CHINA.............. III-53 A.Market Analysis.............. III-53 Current & Future Analysis..............III-53 China: A Market with Huge Untapped Potential for DPP-4 Inhibitor Drugs.............. III-53 Robust Growth Ahead Despite Initial Lag III-53 Product Approval..............III-54 Strategic Corporate Development III-54 B.Market Analytics..............III-55 Table 59: Chinese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-55
Table 60: Chinese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-56
5b. INDIA.............. III-57 A.Market Analysis.............. III-57 DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market..............III-57 First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition..............III-57 Diabetic Epidemic in the Country Spurs Market Growth III-58 Product Launches..............III-58 Strategic Corporate Developments III-59 B.Market Analytics..............III-60 Table 61: Indian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-60
Table 62: Indian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-61
5c. SOUTH KOREA.............. III-62 A.Market Analysis.............. III-62 Rising Competition in the Korean DPP-4 Inhibitor Market III-62 Table 63: Korean DPP-4 Inhibitor Market (2009-2015): No. of DPP-4 Inhibitors on the Market during 2009, 2010, 2011, 2012, 2013, 2014 & 2015 (includes corresponding Graph/Chart).............. III-62 Product Approval..............III-62 B.Market Analytics..............III-63 Table 64: South Korean Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-63
Table 65: South Korean Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-64
5d. REST OF ASIA-PACIFIC..............III-65 A.Market Analysis.............. III-65 Current & Future Analysis..............III-65 Australia.............. III-65 Rising Incidence of Diabetes..............III-65 B.Market Analytics..............III-66 Table 66: Rest of Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-66
Table 67: Rest of Asia-Pacific Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-67
6. REST OF WORLD.............. III-68 A.Market Analysis.............. III-68 Current & Future Analysis..............III-68 Latin America: National Diabetes Programs III-68 A Peek at Brazilian Diabetes Market III-68 Table 68: Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region.............. III-69 United Arab Emirates: Rising Diabetic Cases to Propel Market Demand.............. III-69 Key Statistics: Diabetes Prevalence in Middle East and African Regions..............III-70 Table 69: Prevalence of Diabetes Mellitus in Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region.............. III-70
Table 70: Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region III-71 B.Market Analytics..............III-72 Table 71: Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-72
Table 72: Rest of World Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-73
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 23
The United States (3) Japan (7) Europe (4) - Germany (1) - The United Kingdom (1) - Spain (1) - Rest of Europe (1) Asia-Pacific (Excluding Japan) (9)
Read the full report: http://www.reportlinker.com/p03846707-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article